| Autor: |
Richard G Jung, Omar Abdel-Razek, Pietro Di Santo, Taylor Gillmore, Cameron Stotts, Dwipen Makwana, Joelle Soriano, Robert Moreland, Louis Verreault-Julien, Cheng Yee Goh, Simon Parlow, Caleb Sypkes, Daniel F Ramirez, Mouhannad Sadek, Vincent Chan, Hadi Toeg, Trevor Simard, Michael P V Froeschl, Marino Labinaz, Benjamin Hibbert |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Open heart. 9(2) |
| ISSN: |
2053-3624 |
| Popis: |
ObjectiveAtrial fibrillation (AF) remains a highly prevalent arrhythmia with significant burden on morbidity and mortality. The impact of AF in the revascularised population remains incompletely described. Given the high prevalence of AF in the revascularised population, we sought to evaluate the incidence and prognosis in patients with pre-existing and new-onset AF following revascularisation.MethodsWe used the University of Ottawa Heart Institute Revascularisation Registry to identify patients who underwent revascularisation between August 2015 and March 2020, who were prospectively followed for an average of one year. We conducted a retrospective cohort study analysing the association between AF and clinical outcomes. The primary outcome of interest was 1-year major adverse cardiac events (MACE) defined as a composite of death, myocardial infarction, unplanned revascularisation and cerebrovascular accidents. Moreover, secondary outcomes include the individual components of MACE and bleeding.ResultsA total of 6704 patients underwent revascularisation and completed 1-year clinical follow-up. Median time to follow-up was 12.8 (IQR 11.2–15.9) months. One-year MACE occurred in 166 (21.8%) and 683 (11.5%) patients in AF and non-AF groups, respectively (adjusted HR, 1.61; 95% CI 1.29 to 2.01; pConclusionsPreprocedural and new-onset AF following revascularisation remains highly predictive 1-year MACE. AF should be considered in addition to traditional risk factors for adverse outcomes following revascularisation. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
